48.03
+1.43(+3.07%)
Currency In USD
| Previous Close | 46.6 |
| Open | 46.55 |
| Day High | 48.08 |
| Day Low | 46.04 |
| 52-Week High | 48.09 |
| 52-Week Low | 13.37 |
| Volume | 734,890 |
| Average Volume | 713,830 |
| Market Cap | 1.74B |
| PE | -13.72 |
| EPS | -3.5 |
| Moving Average 50 Days | 41.4 |
| Moving Average 200 Days | 28.69 |
| Change | 1.43 |
If you invested $1000 in Dianthus Therapeutics, Inc. (DNTH) since IPO date, it would be worth $206.74 as of January 22, 2026 at a share price of $48.03. Whereas If you bought $1000 worth of Dianthus Therapeutics, Inc. (DNTH) shares 5 years ago, it would be worth $365.64 as of January 22, 2026 at a share price of $48.03.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 05, 2026 12:00 PM GMT
NEW YORK and WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune dise
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
GlobeNewswire Inc.
Dec 23, 2025 11:00 AM GMT
LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function Top-line results in healthy volunteer
Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference
GlobeNewswire Inc.
Nov 24, 2025 12:00 PM GMT
NEW YORK and WALTHAM, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune dise